Amgen to provide rebates for Repatha patients who have heart attack or stroke
Thousand Oaks-based Amgen announced on May 2 that it has reached a “first-of-its-kind contract” with health care company Harvard Pilgrim. The contract provides Harvard Pilgrim with a rebate for the cost of Repatha for any eligible patient who has a heart attack or stroke while on Repatha. “Amgen is committed to combating cardiovascular disease, one Read More →
Amgen revenues fall but profits increase
Thousand Oaks-based biotech giant Amgen’s total revenues decreased by 1 percent to $5.5 billion during the first quarter of 2017, compared to the same period a year ago, according to an earnings report April 26. The drop was related to the plunge in sales of Enbrel, its rheumatoid arthritis drug. Sales decreased 15 percent due Read More →
Cottage Health settles flesh-eating disease death lawsuit
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Thousand Oaks braces for Amgen staff cuts
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Dubroff: East Ventura County should focus on creating a biotech cluster
When the Business Times broke the story that Amgen was cutting roughly 500 support and operations jobs at its sprawling Thousand Oaks campus, there were gasps — and sighs of relief. Gasps because the world’s largest biotechnology company is the economic engine for the Conejo Valley, East Ventura County and, for that matter, a big Read More →
FDA fast tracks Amgen’s Blincyto leukemia drug
Thousand Oaks-based biotech giant Amgen announced March 29 that the U.S. Food and Drug Administration has fast-tracked the company’s leukemia drug Blincyto for priority review. The drug increases the length of survival among high-risk patients, according to a study released by the New England Journal of Medicine. It almost doubled median overall survival versus chemotherapy among adult patients Read More →
Law firm probing Sientra board of directors
The law firm of Brodsky & Smith has announced an investigation into the board of directors at Sientra, a breast implant manufacturing firm based in Goleta. According to a news release from the law firm, the investigation comes after previous litigation. The complaint alleges that the defendants made false and misleading statements, including failing to Read More →
